The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy
Citations Over TimeTop 15% of 2016 papers
Abstract
Several reports have suggested that peripheral blood-based parameters are associated with host immunity response, which is an essential component of the pathogenesis and progression of cancer. The purpose of the present study was to identify the prognostic significance of various peripheral blood-based biomarkers and to determine the optimal cut-off value suitable for luminal breast cancer patients. We found that lymphocyte-to-monocyte ratio (LMR) was significant prognostic predictors. And the patients with a CEF regimen and LMR ratio ≥ 5.2 gained a good prognosis. This study suggested that the LMR could be regarded as an independent prognostic factor in luminal breast cancer patients. The elevated LMR level also had enhanced 5-fluorouracil sensitivity in luminal breast cancer patients.
Related Papers
- Relapses in paucibacillary patients after treatment with three short-term regimens containing rifampin.(1989)
- Comparison of three regimens containing rifampin for treatment of paucibacillary leprosy patients.(1987)
- The Clinical Study on the Freatment of Multiple Myeloma lombined by the VDA Regimen and Malphalan(2000)
- A Comparison of the Therapeutic Effects of EP and CAP Regimen for Treatment of Advanced Non-small Cell Lung Cancer of Older Patient(2000)
- Clinical Analysis of the Short-term Efficacy and Toxicity of the Advanced Gastric Cancer Treated with ELFP Regimen and EFP Regimen(2000)